Page 1 | Search Results | Blood | American Society of Hematology

1-19 of 19

Sort by

Sort Order Select

Journal Articles

Comparative Effectiveness of Glasdegib or Venetoclax in Combination with Low-Dose Cytarabine Using Simulated Treatment Comparisons

Gabriel Tremblay, DBA, MSc, BS, Patrick Daniele, Mike Dolph, MSc BHSc, Timothy J. Bell, Geoffrey Chan, MD, Andrew Brown, PhD, Joseph C Cappelleri, PhD MPH, MS

Blood (2020) 136 (Supplement 1): 17–18.

https://doi.org/10.1182/blood-2020-137641

Published: 2020

Journal Articles

A Phase 1b Study of Glasdegib in Combination with Azacitidine in Patients with Untreated Higher-Risk Myelodysplastic Syndromes, Acute Myeloid Leukemia, and Chronic Myelomonocytic Leukemia

Mikkael A. Sekeres, MD MS, Michael W. Schuster, MD, Magalie Joris, MD, Jürgen Krauter, MD, Johan A. Maertens, MD PhD, Emmanuel Gyan, MD PhD, Tibor Kovacsovics, MD, Amit Verma, MBBS, Paresh Vyas, MD PhD, Eunice S. Wang, MD, Weidong Wendy Ma, Mirjana Zeremski, MD, Arthur Kudla, Geoffrey Chan, MD, Amer M. Zeidan, MBBS, MHS

Blood (2019) 134 (Supplement_1): 177.

https://doi.org/10.1182/blood-2019-124050

Published: 2019

Journal Articles

Overall Survival of Glasdegib in Combination with Low-Dose Cytarabine and Azacitidine By Bone Marrow Blasts Among Adult Patients with Previously Untreated Acute Myeloid Leukemia: Comparative Effectiveness Using Indirect Treatment Comparisons

Sophie Van Beekhuizen, MSc, Timothy J Bell, MHA, Ana Gezin, MSc, Joseph C Cappelleri, PhD MPH, MS, Bart Heeg, PhD, Carl Selya-Hammer, MSc, Majed Charaan, MSc, MBA, Geoffrey Chan, MD

Blood (2019) 134 (Supplement_1): 5846.

https://doi.org/10.1182/blood-2019-125852

Published: 2019

Journal Articles

Clinical Benefit of Glasdegib in Combination with Azacitidine or Low-Dose Cytarabine in Patients with Acute Myeloid Leukemia

Amer M. Zeidan, MBBS, MHS, Michael W. Schuster, MD, Jürgen Krauter, MD, Johan A. Maertens, MD PhD, Emmanuel Gyan, MD PhD, Magalie Joris, MD, Tobias F Menne, MD PhD FRCPath, Paresh Vyas, MD PhD, Weidong Wendy Ma, Ashleigh O'Connell, Mirjana Zeremski, MD, Arthur Kudla, Geoffrey Chan, MD, Mikkael A. Sekeres, MD MS

Blood (2019) 134 (Supplement_1): 3916.

https://doi.org/10.1182/blood-2019-124034

Published: 2019

Journal Articles

Clinical Responses of Glasdegibplus Low-Dose Ara-C, Azacitidine, and Decitabine Among Acute Myeloid Leukemia (AML) Patients Ineligible to Receive Intensive Chemotherapy: Comparative Effectiveness Using Indirect Treatment Comparison (ITC) Methods

Tracy Westley, MPH, Anna Forsythe, PharmD, MSc, MBA, Timothy J Bell, Joseph C Cappelleri, PhD MPH, MS, Gabriel Tremblay, DBA, MSc, BS, Geoffrey Chan, MD

Blood (2018) 132 (Supplement 1): 2709.

https://doi.org/10.1182/blood-2018-99-111931

Published: 2018

Journal Articles

Glasdegib in Addition to Intensive or Non-Intensive Chemotherapy in Patients with Acute Myeloid Leukemia: Safety Analysis of Glasdegib 'On Target' Adverse Events

Jorge E. Cortes, MD, Cristina Papayannidis, Catriona Jamieson, MD PhD, Gary J. Schiller, MD, Anna Candoni, MD, Brian Leber, MD, Claudia D. Baldus, MD, José A. Pérez-Simón, MD PhD, Weidong Wendy Ma, Corrado Gallo Stampino, Ashleigh O'Connell, Mirjana Zeremski, MD, Geoffrey Chan, MD, Mikkael A. Sekeres, MD MS

Blood (2018) 132 (Supplement 1): 2732.

https://doi.org/10.1182/blood-2018-99-110934

Published: 2018

Journal Articles

Biomarkers of Overall Survival and Response to Glasdegib and Intensive or Non-Intensive Chemotherapy in Patients with Acute Myeloid Leukemia

Jorge E. Cortes, MD, Akil Merchant, MD, Catriona Jamieson, MD PhD, Daniel A Pollyea, MD, Michael Heuser, MD, Geoffrey Chan, MD, Panpan Wang, Keith A Ching, Jillian Johnson, Thomas O'Brien

Blood (2018) 132 (Supplement 1): 2733.

https://doi.org/10.1182/blood-2018-99-111239

Published: 2018

Journal Articles

Comparative Effectiveness of Combination Glasdegib+ Low-Dose Cytarabine (GLAS+LDAC) Vs Combination Venetoclax + Low-Dose Cytarabine (VEN+LDAC) Among Older Acute Myeloid Leukemia (AML) Patients Ineligible for Intensive Chemotherapy (NIC): Indirect Treatment Comparison (ITC) Methods

Tracy Westley, MPH, Anna Forsythe, PharmD, MSc, MBA, Timothy J Bell, Joseph C Cappelleri, PhD MPH, MS, Geoffrey Chan, MD, Gabriel Tremblay, DBA, MSc, BS

Blood (2018) 132 (Supplement 1): 1429.

https://doi.org/10.1182/blood-2018-99-111971

Published: 2018

Journal Articles

Population Pharmacokinetic/Pharmacodynamic Evaluation of the Relationship between Glasdegib Treatment/ Exposure and Overall Survival in AML Patients

Swan Lin, PharmD, M. Naveed Shaik, PhD, Geoffrey Chan, MD, Jorge E. Cortes, MD, Ana Ruiz-Garcia, PharmD, PhD

Blood (2018) 132 (Supplement 1): 1450.

https://doi.org/10.1182/blood-2018-99-111132

Published: 2018

Journal Articles

Phase I/II Trial of Glasdegib in Heavily Pre-Treated Patients with Primary or Secondary Myelofibrosis

Aaron T. Gerds, MDMS, Tetsuzo Tauchi, MD, Ellen K. Ritchie, MD, Michael W. Deininger, MD PhD, Catriona HM Jamieson, MD PhD, Ruben Mesa, MD FACP, Mark Lawrence Heaney, MD PhD, Norio Komatsu, MD PhD, Hironobu Minami, MD PhD, M. Naveed Shaik, PhD, Xiaoxi Zhang, PhD, Christine DiRienzo, PhD, Mirjana Zeremski, MD, Geoffrey Chan, MD, Moshe Talpaz, MD

Blood (2017) 130 (Supplement 1): 258.

https://doi.org/10.1182/blood.V130.Suppl_1.258.258

Published: 2017

Journal Articles

Covariate Adjusted Indirect Treatment Comparison (ITC) of Glasdegib Plus Low Dose Ara-C Versus a Hypomethylating Agent for Acute Myeloid Leukemia Patients Ineligible for Intensive Chemotherapy

Gabriel Tremblay, DBA, MSc, BS, Bhakti Arondekar, BPharm, MBA, PhD, Geoffrey Chan, MD, Anastasiya Shor, PharmD, Anna Forsythe, PharmD, MSc, MBA, Su Yun, MD MPH

Blood (2017) 130 (Supplement 1): 5665.

https://doi.org/10.1182/blood.V130.Suppl_1.5665.5665

Published: 2017

Journal Articles

A Phase 2 Randomized Study of Low Dose Ara-C with or without Glasdegib (PF-04449913) in Untreated Patients with Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome

Jorge E. Cortes, MD, Florian H. Heidel, MD, Michael Heuser, MD, Walter Fiedler, MD, B. Douglas Smith, MD, Tadeusz Robak, MD, Pau Montesinos Fernandez, MD, Weidong Wendy Ma, PhD, M. Naveed Shaik, PhD, Mirjana Zeremski, MD, Ashleigh O'Connell, Geoffrey Chan, MD

Blood (2016) 128 (22): 99.

https://doi.org/10.1182/blood.V128.22.99.99

Published: 2016

Journal Articles

Phase 3, Placebo-Controlled, ASPIRE Study (TRC114968) of Eltrombopag (EPAG) Treatment of Thrombocytopenia (TCP) in Advanced Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML): Assessment of Clinical Benefit, Safety, and Tolerability

Moshe Mittelman, MD, Uwe Platzbecker, MD, Boris V Afanasyev, Professor, Sebastian Grosicki, MD PhD, Raymond SM Wong, MD, Achilles Anagnostopoulos, MD, Benjamin Brenner, MD, Claudio Denzlinger, MD, Giuseppe Rossi, MD, Arnon Nagler, MD MSc, Ana Isabel Rosell Mas, PhD, Frank Mannino, PhD, Nicole L. Stone, PhD, Geoffrey Chan, MD, Yasser Mostafa Kamel, MD MSc, MBA, Dominik L.D. Selleslag, MD

Blood (2015) 126 (23): 1661.

https://doi.org/10.1182/blood.V126.23.1661.1661

Published: 2015

Journal Articles

Investigating Effects of Cyclosporine on Eltrombopag Pharmacokinetics in Healthy Volunteers: A Phase 1 Crossover, Drug-Drug Interaction Study

Jianping Zhang, PhD, Connie L. Erickson-Miller, PhD, Geoffrey Chan, MD, Yan Yan Zhou, PhD

Blood (2015) 126 (23): 4791.

https://doi.org/10.1182/blood.V126.23.4791.4791

Published: 2015

Journal Articles

Chemoimmunotherapy with O-FC in previously untreated patients with chronic lymphocytic leukemia

William G. Wierda, Thomas J. Kipps, Jan Dürig, Laimonas Griskevicius, Stephan Stilgenbauer, Jiří Mayer, Lukáš Smolej, Georg Hess, Rasa Griniute, Francisco J. Hernandez-Ilizaliturri, Swaminathan Padmanabhan, Michele Gorczyca, Chai-Ni Chang, Geoffrey Chan, Ira Gupta, Tina G. Nielsen, Charlotte A. Russell

Blood (2011) 117 (24): 6450–6458.

https://doi.org/10.1182/blood-2010-12-323980

Published: 2011

Includes: Supplemental data

Journal Articles

Correlation Between Serum Ofatumumab Concentrations, Baseline Patient Characteristics and Clinical Outcomes in Patients with Fludarabine-Refractory Chronic Lymphocytic Leukemia (CLL) Treated with Single-Agent Ofatumumab.

Blood (2009) 114 (22): 3433.

https://doi.org/10.1182/blood.V114.22.3433.3433

Published: 2009

Journal Articles

Ofatumumab Combined with Fludarabine and Cyclophosphamide (O-FC) Shows High Activity in Patients with Previously Untreated Chronic Lymphocytic Leukemia (CLL): Results From a Randomized, Multicenter, International, Two-Dose, Parallel Group, Phase II Trial.

William G Wierda, Thomas J Kipps, Jan Dürig, Laimonas Griskevicius, Stephan Stilgenbauer, Jiri Mayer, Lukas Smolej, Georg Hess, Rasa Griniute, Francisco J Hernandez-Ilizaliturri, Swaminathan Padmanabhan, Michele Gorczyca, Geoffrey Chan, Ira Gupta, Marc Andersen, Claus Strange, Tina G Nielsen, Charlotte A Russell

Blood (2009) 114 (22): 207.

https://doi.org/10.1182/blood.V114.22.207.207

Published: 2009

Journal Articles

Ofatumumab (HuMax-CD20), a Novel CD20 Monoclonal Antibody, Is An Active Treatment for Patients with CLL Refractory to Both Fludarabine and Alemtuzumab or Bulky Fludarabine-Refractory Disease: Results from the Planned Interim Analysis of An International Pivotal Trial

Blood (2008) 112 (11): 328.

https://doi.org/10.1182/blood.V112.11.328.328

Published: 2008

Journal Articles

Complete remission in a patient with acute myelogenous leukemia treated with erlotinib for non–small-cell lung cancer

Geoffrey Chan, Monika Pilichowska

Blood (2007) 110 (3): 1079–1080.

https://doi.org/10.1182/blood-2007-01-069856

Published: 2007

NARROW

Comparative Effectiveness of Glasdegib or Venetoclax in Combination with Low-Dose Cytarabine Using Simulated Treatment Comparisons

A Phase 1b Study of Glasdegib in Combination with Azacitidine in Patients with Untreated Higher-Risk Myelodysplastic Syndromes, Acute Myeloid Leukemia, and Chronic Myelomonocytic Leukemia

Overall Survival of Glasdegib in Combination with Low-Dose Cytarabine and Azacitidine By Bone Marrow Blasts Among Adult Patients with Previously Untreated Acute Myeloid Leukemia: Comparative Effectiveness Using Indirect Treatment Comparisons

Clinical Benefit of Glasdegib in Combination with Azacitidine or Low-Dose Cytarabine in Patients with Acute Myeloid Leukemia

Clinical Responses of Glasdegibplus Low-Dose Ara-C, Azacitidine, and Decitabine Among Acute Myeloid Leukemia (AML) Patients Ineligible to Receive Intensive Chemotherapy: Comparative Effectiveness Using Indirect Treatment Comparison (ITC) Methods

Glasdegib in Addition to Intensive or Non-Intensive Chemotherapy in Patients with Acute Myeloid Leukemia: Safety Analysis of Glasdegib 'On Target' Adverse Events

Biomarkers of Overall Survival and Response to Glasdegib and Intensive or Non-Intensive Chemotherapy in Patients with Acute Myeloid Leukemia

Comparative Effectiveness of Combination Glasdegib+ Low-Dose Cytarabine (GLAS+LDAC) Vs Combination Venetoclax + Low-Dose Cytarabine (VEN+LDAC) Among Older Acute Myeloid Leukemia (AML) Patients Ineligible for Intensive Chemotherapy (NIC): Indirect Treatment Comparison (ITC) Methods

Population Pharmacokinetic/Pharmacodynamic Evaluation of the Relationship between Glasdegib Treatment/ Exposure and Overall Survival in AML Patients

Phase I/II Trial of Glasdegib in Heavily Pre-Treated Patients with Primary or Secondary Myelofibrosis

Covariate Adjusted Indirect Treatment Comparison (ITC) of Glasdegib Plus Low Dose Ara-C Versus a Hypomethylating Agent for Acute Myeloid Leukemia Patients Ineligible for Intensive Chemotherapy

A Phase 2 Randomized Study of Low Dose Ara-C with or without Glasdegib (PF-04449913) in Untreated Patients with Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome

Phase 3, Placebo-Controlled, ASPIRE Study (TRC114968) of Eltrombopag (EPAG) Treatment of Thrombocytopenia (TCP) in Advanced Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML): Assessment of Clinical Benefit, Safety, and Tolerability

Investigating Effects of Cyclosporine on Eltrombopag Pharmacokinetics in Healthy Volunteers: A Phase 1 Crossover, Drug-Drug Interaction Study

Chemoimmunotherapy with O-FC in previously untreated patients with chronic lymphocytic leukemia

Correlation Between Serum Ofatumumab Concentrations, Baseline Patient Characteristics and Clinical Outcomes in Patients with Fludarabine-Refractory Chronic Lymphocytic Leukemia (CLL) Treated with Single-Agent Ofatumumab.

Ofatumumab Combined with Fludarabine and Cyclophosphamide (O-FC) Shows High Activity in Patients with Previously Untreated Chronic Lymphocytic Leukemia (CLL): Results From a Randomized, Multicenter, International, Two-Dose, Parallel Group, Phase II Trial.

Ofatumumab (HuMax-CD20), a Novel CD20 Monoclonal Antibody, Is An Active Treatment for Patients with CLL Refractory to Both Fludarabine and Alemtuzumab or Bulky Fludarabine-Refractory Disease: Results from the Planned Interim Analysis of An International Pivotal Trial

Complete remission in a patient with acute myelogenous leukemia treated with erlotinib for non–small-cell lung cancer

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only